Can a Dual-Antibody combo outsmart advanced lung cancer?
NCT ID NCT06969027
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This clinical trial is testing whether a new investigational drug called JS207, which targets two proteins involved in tumor growth (PD-1 and VEGF), can be safely combined with standard chemotherapy as a first-line treatment for advanced non-small cell lung cancer (NSCLC). The study will enroll about 69 adults with locally advanced, metastatic, or recurrent NSCLC who have not received prior systemic therapy for their advanced disease. Participants will receive one of two chemotherapy regimens (pemetrexed plus a platinum drug, or paclitaxel plus a platinum drug) along with JS207, and the study will measure how well the tumors respond and how long patients go without progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- JS207 (a dual antibody targeting PD-1 and VEGF) combined with chemotherapy (pemetrexed or paclitaxel plus a platinum drug)
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for advanced non-small cell lung cancer, potentially improving tumor shrinkage and delaying disease progression.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not be conclusive. The combination may cause side effects, and its effectiveness compared to existing therapies is not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shandong First Medical University Affiliated Neoplasm Hospital
Jinan, Shandong, 250117, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?